NCT00537290View on ClinicalTrials.gov

A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Antiphospholipid Syndrome

Interventions

DRUG

Rituximab

Rituximab 1000mg IV on Days 0 and 15

Trial Locations (1)

10021

Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Hospital for Special Surgery, New York

OTHER

NCT00537290 - A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome | Biotech Hunter | Biotech Hunter